

Laura Airas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7061886/publications.pdf>

Version: 2024-02-01

87
papers

3,340
citations

159525

30
h-index

155592

55
g-index

91
all docs

91
docs citations

91
times ranked

4605
citing authors

#	ARTICLE	IF	CITATIONS
1	Smouldering multiple sclerosis: the “real MS”™. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642110667.	1.5	72
2	Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation. <i>EJNMMI Research</i> , 2022, 12, 6.	1.1	7
3	Association between microglial activation and serum kynurenine pathway metabolites in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103667.	0.9	5
4	Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET. <i>Brain Communications</i> , 2022, 4, fcab301.	1.5	11
5	Innate Immune Cell-Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	10
6	Microglia in multiple sclerosis “ pathogenesis and imaging. <i>Current Opinion in Neurology</i> , 2022, 35, 299-306.	1.8	17
7	Oral Doxycycline Compared to Intravenous Ceftriaxone in the Treatment of Lyme Neuroborreliosis: A Multicenter, Equivalence, Randomized, Open-label Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, 1323-1331.	2.9	26
8	High serum neurofilament associates with diffuse white matter damage in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	25
9	Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2021, 18, 30.	3.1	6
10	Fingolimod treatment reverses signs of diffuse white matter damage in multiple sclerosis: A pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102690.	0.9	3
11	Whole Brain Adiabatic T 1rho and Relaxation Along a Fictitious Field Imaging in Healthy Volunteers and Patients With Multiple Sclerosis: Initial Findings. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 866-879.	1.9	1
12	Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102810.	0.9	21
13	Effect of dopaminergic medication on adenosine 2A receptor availability in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 40-44.	1.1	4
14	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. <i>Journal of Neuroimmunology</i> , 2021, 357, 577627.	1.1	33
15	Positron emission tomography in multiple sclerosis “ straight to the target. <i>Nature Reviews Neurology</i> , 2021, 17, 663-675.	4.9	27
16	Synaptic Loss in Multiple Sclerosis: A Systematic Review of Human Post-mortem Studies. <i>Frontiers in Neurology</i> , 2021, 12, 782599.	1.1	8
17	Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. <i>Multiple Sclerosis Journal</i> , 2020, 26, 210-219.	1.4	105
18	Frequency and etiology of acute transverse myelitis in Southern Finland. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102562.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. <i>Brain</i> , 2020, 143, 3318-3330.	3.7	71
20	Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	26
21	Exposure to natalizumab during pregnancy and lactation is safe – No. <i>Multiple Sclerosis Journal</i> , 2020, 26, 889-891.	1.4	6
22	Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101980.	0.9	18
23	Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102058.	0.9	7
24	Pregnancy-Induced Changes in microRNA Expression in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 552101.	2.2	12
25	Effects of age, BMI and sex on the glial cell marker TSPO – a multicentre [11C]PBR28 HRRT PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2329-2338.	3.3	70
26	Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101385.	0.9	2
27	Cessation of anti-VLA-4 therapy in a focal rat model of multiple sclerosis causes an increase in neuroinflammation. <i>EJNMMI Research</i> , 2019, 9, 38.	1.1	4
28	Natalizumab treatment reduces microglial activation in the white matter of the MS brain. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e574.	3.1	34
29	Folate receptor-targeted positron emission tomography of experimental autoimmune encephalomyelitis in rats. <i>Journal of Neuroinflammation</i> , 2019, 16, 252.	3.1	10
30	Microglial activation, white matter tract damage, and disability in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e443.	3.1	51
31	Severe neutropenia after rituximab-treatment of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 3-5.	0.9	21
32	Vascular adhesion protein-1 is actively involved in the development of inflammatory lesions in rat models of multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2018, 15, 128.	3.1	12
33	Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. <i>Neurology</i> , 2018, 90, 849-851.	1.5	32
34	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , The, 2018, 17, 405-415.	4.9	238
35	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 11-19.	0.9	17
36	Evaluation of Microglial Activation in Multiple Sclerosis Patients Using Positron Emission Tomography. <i>Frontiers in Neurology</i> , 2018, 9, 181.	1.1	51

#	ARTICLE	IF	CITATIONS
37	Positron emission tomography imaging in evaluation of MS pathology in vivo. Multiple Sclerosis Journal, 2018, 24, 1399-1412.	1.4	22
38	Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis. Journal of Nuclear Medicine, 2017, 58, 1646-1651.	2.8	63
39	Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. Journal of the Neurological Sciences, 2017, 380, 142-147.	0.3	30
40	Imaging of microglial activation in MS using PET: Research use and potential future clinical application. Multiple Sclerosis Journal, 2017, 23, 496-504.	1.4	24
41	<i>In Vivo</i> PET Imaging of Adenosine 2A Receptors in Neuroinflammatory and Neurodegenerative Disease. Contrast Media and Molecular Imaging, 2017, 2017, 1-15.	0.4	27
42	Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells. Neurology: Neuroimmunology and Neuroinflammation, 2016, 3, e292.	3.1	29
43	Utilization of PET imaging in differential diagnostics between a tumefactive multiple sclerosis lesion and low-grade glioma. Multiple Sclerosis and Related Disorders, 2016, 9, 147-149.	0.9	14
44	Successive pregnancies in multiple sclerosis. Neurology, 2016, 87, 1316-1317.	1.5	1
45	Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients. Journal of NeuroImmune Pharmacology, 2016, 11, 611-612.	2.1	3
46	Hormonal and gender-related immune changes in multiple sclerosis. Acta Neurologica Scandinavica, 2015, 132, 62-70.	1.0	51
47	Elevated levels of soluble CD26 and CD30 in multiple sclerosis. Clinical and Experimental Neuroimmunology, 2015, 6, 419-425.	0.5	0
48	In Vivo PET Imaging Demonstrates Diminished Microglial Activation After Fingolimod Treatment in an Animal Model of Multiple Sclerosis. Journal of Nuclear Medicine, 2015, 56, 305-310.	2.8	57
49	Automated Reference Region Extraction and Population-Based Input Function for Brain [¹¹ C]TMSX PET Image Analyses. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 157-165.	2.4	40
50	Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients. Multiple Sclerosis and Related Disorders, 2015, 4, 334-338.	0.9	13
51	No evidence of human herpesvirus DNA in the CSF of multiple sclerosis patients. Neurological Sciences, 2015, 36, 1053-1054.	0.9	0
52	Imaging neuroinflammation in multiple sclerosis using TSPO-PET. Clinical and Translational Imaging, 2015, 3, 461-473.	1.1	41
53	Elevated concentration of C-reactive protein is associated with pregnancy-related co-morbidities but not with relapse activity in multiple sclerosis. Neurological Sciences, 2015, 36, 441-447.	0.9	4
54	Labour-associated increase in C-reactive protein concentration is not predictive of postpartum relapse activity among mothers with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1790-1791.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Clinical Relevance of Brain Volume Measures in Multiple Sclerosis. <i>CNS Drugs</i> , 2014, 28, 147-156.	2.7	254
56	Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner. <i>Therapeutic Advances in Neurological Disorders</i> , 2014, 7, 137-149.	1.5	9
57	Detection of Microglial Activation in an Acute Model of Neuroinflammation Using PET and Radiotracers ¹¹ C-(<i>R</i>)-PK11195 and ¹⁸ F-GE-180. <i>Journal of Nuclear Medicine</i> , 2014, 55, 466-472.	2.8	127
58	In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹ C-PK11195. <i>Journal of Nuclear Medicine</i> , 2014, 55, 939-944.	2.8	132
59	Alteration of prolyl oligopeptidase and activated Î±2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome. <i>Biochemical Pharmacology</i> , 2013, 85, 1783-1794.	2.0	20
60	Adenosine A2A Receptors in Secondary Progressive Multiple Sclerosis: A [¹¹ C]TMSX Brain PET Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1394-1401.	2.4	79
61	Pregnancy and multiple sclerosis. <i>Obstetric Medicine</i> , 2012, 5, 94-97.	0.5	19
62	Lower brain diffusivity in postpartum period compared to late pregnancy: results from a prospective imaging study of multiple sclerosis patients. <i>Neuroradiology</i> , 2012, 54, 823-828.	1.1	9
63	Janus head: the dual role of HLA-G in CNS immunity. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 407-416.	2.4	11
64	Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 139-168.	1.5	76
65	Pregnancy and Multiple Sclerosis. , 2011, , 1-11.		0
66	Development of an immunoassay for the detection of cystatin C dimers. <i>Journal of Immunological Methods</i> , 2010, 355, 14-20.	0.6	2
67	Carbon monoxide poisoning-induced nigrostriatal dopaminergic dysfunction detected using positron emission tomography (PET). <i>NeuroToxicology</i> , 2010, 31, 403-407.	1.4	17
68	CD73 is expressed on invading T lymphocytes in the inflamed peripheral nerve. <i>Muscle and Nerve</i> , 2009, 40, 287-289.	1.0	6
69	IFNÎ² regulates CD73 and adenosine expression at the blood-brain barrier. <i>European Journal of Immunology</i> , 2008, 38, 2718-2726.	1.6	72
70	Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. <i>Clinical and Experimental Immunology</i> , 2008, 151, 235-243.	1.1	99
71	Vascular adhesion protein-1 in human ischaemic stroke. <i>Neuropathology and Applied Neurobiology</i> , 2008, 34, 394-402.	1.8	33
72	Methanol intoxication-induced nigrostriatal dysfunction detected using 6-[¹⁸ F]fluoro-l-dopa PET. <i>NeuroToxicology</i> , 2008, 29, 671-674.	1.4	8

#	ARTICLE	IF	CITATIONS
73	CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9325-9330.	3.3	185
74	CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta. <i>Neurological Research</i> , 2007, 29, 763-766.	0.6	12
75	Clinical and immunologic evaluation of women with multiple sclerosis during and after pregnancy. <i>Gender Medicine</i> , 2007, 4, 45-55.	1.4	43
76	Postpartum-activation of multiple sclerosis is associated with down-regulation of tolerogenic HLA-G. <i>Journal of Neuroimmunology</i> , 2007, 187, 205-211.	1.1	42
77	Mechanism of Action of IFN-beta in the Treatment of Multiple Sclerosis: A Special Reference to CD73 and Adenosine. <i>Annals of the New York Academy of Sciences</i> , 2007, 1110, 641-648.	1.8	32
78	Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. <i>Neurological Sciences</i> , 2007, 28, 121-126.	0.9	145
79	Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2006, 177, 132-135.	1.1	36
80	Successful pregnancy of a patient with Balo's concentric sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 346-348.	1.4	7
81	Riedel's thyroiditis in a patient with multiple sclerosis. <i>Neuroendocrinology Letters</i> , 2005, 26, 67-8.	0.2	4
82	IFN- γ Induced Adenosine Production on the Endothelium: A Mechanism Mediated by CD73 (Ecto-5'-Nucleotidase) Up-Regulation. <i>Journal of Immunology</i> , 2004, 172, 1646-1653.	0.4	81
83	Positron emission tomography as an aid in the diagnosis and follow-up of Riedel's thyroiditis. <i>European Journal of Internal Medicine</i> , 2004, 15, 186-189.	1.0	15
84	CD73 Engagement Promotes Lymphocyte Binding to Endothelial Cells Via a Lymphocyte Function-Associated Antigen-1-Dependent Mechanism. <i>Journal of Immunology</i> , 2000, 165, 5411-5417.	0.4	79
85	CD73 and Adhesion of B-Cells to Follicular Dendritic Cells. <i>Leukemia and Lymphoma</i> , 1998, 29, 37-47.	0.6	21
86	Differential Regulation and Function of CD73, a Glycosyl-Phosphatidylinositol-linked 70-kD Adhesion Molecule, on Lymphocytes and Endothelial Cells. <i>Journal of Cell Biology</i> , 1997, 136, 421-431.	2.3	148
87	CD73 mediates lymphocyte binding to vascular endothelium in inflamed human skin. <i>European Journal of Immunology</i> , 1997, 27, 248-254.	1.6	29